author-photo

Carol M. Amato

Anschutz Medical Campus

38

Papers

770

Citations

Citation Trend

Filter By

Papers (38) Sort By

Journal Conference Others

A Novel Regimen for Treating Melanoma: MCL1 Inhibitors and Azacitidine.

2021 Pharmaceuticals, policy and law
Show All
- Source
- Cite
- Save
Citations (0)
543 The high expression of pro-apoptotic BCL2 family members in uveal melanomas contribute to their sensitivity to MCL1 inhibitors

2021 Journal of Investigative Dermatology
Show All
- Source
- Cite
- Save
Citations (0)
Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor–Resistant Melanoma

2021 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (0)
Melanoma Metastases to the Adrenal Gland Are Highly Resistant to Immune Checkpoint Inhibitors.

2021 Journal of The National Comprehensive Cancer Network
Show All
- Source
- Cite
- Save
Citations (0)
MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells.

2020 Cell Death and Disease
Show All
- Source
- Cite
- Save
Citations (22)
674 The effective killing of the difficult-to-treat melanomas with the combinations of MCL1 inhibitors S63845/MIK665 plus Navitoclax

2020 Journal of Investigative Dermatology
Show All
- Source
- Cite
- Save
Citations (0)
Simultaneously Inhibiting BCL2 and MCL1 Is a Therapeutic Option for Patients with Advanced Melanoma

2020 Cancers
Show All
- Source
- Cite
- Save
Citations (6)
Abstract 1805: The therapeutic potential of 5-Azacitidine plus various BH3 mimetics in melanoma

2020
Show All
- Source
- Cite
- Save
Citations (0)
Circulating CD8+ MAIT cells correlate with improved outcomes in anti-PD1 treated melanoma patients.

2020 medRxiv
Show All
- Source
- Cite
- Save
Citations (0)
Clinical and molecular features of subungual melanomas are site-specific and distinct from acral melanomas

2020 Melanoma Research
Show All
- Source
- Cite
- Save
Citations (5)